CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology
company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim
data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.
CAMBRIDGE, Mass., July 13, 2017 — Moderna Therapeutics, a clinical stage biotechnology
company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new
data demonstrating that its Zika mRNA vaccine prevented Zika virus transmission from pregnant mice to their fetuses.